EDMONTON, Jan. 30 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced results ...
EDMONTON, April 30 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), today announced that the University of Alberta, a major shareholder of the Company, has ...
EDMONTON, AB, May 3 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), today announced its updated corporate strategy. The Company's new strategy will encompass ...
BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment ...
TORONTO, Dec 18 (Reuters) - Shares of BioMS Medical Corp climbed more than 50 percent on Tuesday after the small Canadian biotechnology company signed a global licensing and development agreement with ...
Positive interim review from Phase II/III trial in secondary progressive multiple sclerosis triggered the payment. BioMS Medical received $10 million from Eli Lilly as a result of positive initial ...
Shares of BioMS Medical Corp. jumped 38 percent Tuesday after the company unveiled plans to license its Phase III multiple sclerosis drug MBP8298 to Eli Lilly and Co. in a deal potentially worth more ...
TORONTO, Jan 19 (Reuters) - BioMS Medical Corp. said on Friday it has received U.S. Food and Drug Administration approval to begin a Phase 3 trial of its multiple sclerosis treatment. The two-year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results